TELA Bio, Inc. (TELA)
0.8301
+0.01
(+1.05%)
USD |
NASDAQ |
Sep 08, 16:00
0.85
+0.02
(+2.40%)
Pre-Market: 20:00
TELA Bio Enterprise Value : 63.40M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 63.40M |
| September 04, 2026 | 63.02M |
| September 03, 2026 | 61.20M |
| September 02, 2026 | 59.92M |
| September 01, 2026 | 61.66M |
| August 31, 2026 | 59.27M |
| August 28, 2026 | 57.57M |
| August 27, 2026 | 55.33M |
| August 26, 2026 | 57.17M |
| August 25, 2026 | 57.57M |
| August 24, 2026 | 55.51M |
| August 21, 2026 | 55.16M |
| August 20, 2026 | 54.85M |
| August 19, 2026 | 55.19M |
| August 18, 2026 | 55.02M |
| August 17, 2026 | 55.33M |
| August 14, 2026 | 55.07M |
| August 13, 2026 | 56.58M |
| August 12, 2026 | 58.48M |
| August 11, 2026 | 61.61M |
| August 10, 2026 | 67.88M |
| August 07, 2026 | 65.19M |
| August 06, 2026 | 64.74M |
| August 05, 2026 | 67.21M |
| August 04, 2026 | 66.83M |
| Date | Value |
|---|---|
| August 03, 2026 | 59.36M |
| July 31, 2026 | 58.91M |
| July 30, 2026 | 58.01M |
| July 29, 2026 | 56.56M |
| July 28, 2026 | 56.23M |
| July 27, 2026 | 55.33M |
| July 24, 2026 | 57.17M |
| July 23, 2026 | 58.06M |
| July 22, 2026 | 59.04M |
| July 21, 2026 | 58.49M |
| July 20, 2026 | 58.47M |
| July 17, 2026 | 58.96M |
| July 16, 2026 | 59.84M |
| July 15, 2026 | 61.40M |
| July 14, 2026 | 59.83M |
| July 13, 2026 | 62.83M |
| July 10, 2026 | 64.16M |
| July 09, 2026 | 64.65M |
| July 08, 2026 | 62.05M |
| July 07, 2026 | 66.26M |
| July 06, 2026 | 61.44M |
| July 02, 2026 | 58.53M |
| July 01, 2026 | 58.47M |
| June 30, 2026 | 59.81M |
| June 29, 2026 | 49.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Abbott Laboratories | 210.25B |
| AngioDynamics, Inc. | 591.77M |
| Alphatec Holdings, Inc. | 1.912B |
| AtriCure, Inc. | 2.639B |
| Baxter International, Inc. | 19.53B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.26M |
| Revenue (Quarterly) | 19.29M |
| Total Expenses (Quarterly) | 30.55M |
| EPS Diluted (Quarterly) | -0.1962 |
| Gross Profit Margin (Quarterly) | 72.28% |
| Profit Margin (Quarterly) | -58.38% |
| Earnings Yield | -93.35% |
| Normalized Earnings Yield | -91.89 |